SCHEMBL5538602

SCHEMBL5538602

COC(CC1(C(N)=O)CCCCC1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 2/20 0.39
CETP P11597 3/20 0.39
KMT2A Q03164 2/20 0.39
PABPC1 P11940 1/20 0.39
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
CHRM2 P08172 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
CHRM4 P08173 1/20 0.38
LMNA P02545 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
PKM P14618 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ADRB1 P08588 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6926712 0.99 MME (0.39) MMECETPKMT2APABPC1APOBEC3A
SCHEMBL6470515 0.83 MME (0.35) MMECETPKMT2APABPC1APOBEC3A
SCHEMBL518234 0.78 MME (0.39) MMECETPKMT2ACHRM2CHRM1
SCHEMBL4984849 0.78 CHRM2 (0.39) KMT2APABPC1APOBEC3AAPOBEC3GCHRM2
SCHEMBL6472115 0.75 MME (0.37) MMECETPKMT2AMEN1
SCHEMBL535200 0.75 CYP2D6 (0.38) MMEKMT2ALMNASMN1; SMN2MEN1
SCHEMBL2432098 0.74 CYP1A2 (0.53) KMT2ALMNAMEN1ALDH1A1CYP1A2
SCHEMBL2432526 0.74 CYP1A2 (0.53) KMT2ALMNAMEN1ALDH1A1CYP1A2
SCHEMBL4780750 0.71 ALDH1A1 (0.51) KMT2ALMNASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL10749458 0.70 OPRM1 (0.39) CHRM2CHRM1CHRM3CHRM4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 MME 925/4885CETP 2420/4885KMT2A 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.